[{"orgOrder":0,"company":"Amniox Medical","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Amniox Announces Initiation for First of Two Phase 3 Clinical Trials of Cryopreserved Umbilical Cord TTAX01 Allograft","therapeuticArea":"Podiatry","highestDevelopmentStatus":"Phase III","country":"U.S.A","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"June 2020","url1":"","url2":"","graph1":"Cell and Gene therapy","graph2":"Phase III"},{"orgOrder":0,"company":"PolarityTE","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"PolarityTE Announces Positive Top-Line Data from Interim Analysis of SkinTE\u2122 Diabetic Foot Ulcer Trial","therapeuticArea":"Podiatry","highestDevelopmentStatus":"Undisclosed","country":"U.S.A","productType":"Cell and Gene therapy","productStatus":"Undisclosed","date":"July 2020","url1":"","url2":"","graph1":"Cell and Gene therapy","graph2":"Undisclosed"},{"orgOrder":0,"company":"Centaur Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Centaur Pharma Launches Novel Topical Solution WoxHeal for the Treatment of Diabetic Foot Ulcer","therapeuticArea":"Podiatry","highestDevelopmentStatus":"Approved","country":"INDIA","productType":"Small molecule","productStatus":"Approved","date":"October 2020","url1":"","url2":"","graph1":"Small molecule","graph2":"Approved"},{"orgOrder":0,"company":"Cynata Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Cynata Advances Planned Clinical Trial in Diabetic Foot Ulcers in MoU With TekCyte","therapeuticArea":"Podiatry","highestDevelopmentStatus":"Preclinical","country":"AUSTRALIA","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"March 2021","url1":"","url2":"","graph1":"Cell and Gene therapy","graph2":"Preclinical"},{"orgOrder":0,"company":"MediWound","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"MediWound Enrolls First Patient in Phase 2 Pharmacology Study of EscharEx","therapeuticArea":"Podiatry","highestDevelopmentStatus":"Phase II","country":"ISRAEL","productType":"Large molecule","productStatus":"New Molecular Entity","date":"April 2021","url1":"","url2":"","graph1":"Large molecule","graph2":"Phase II"},{"orgOrder":0,"company":"MediWound","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"MediWound Completes Patient Enrollment for Interim Assessment of its U.S. EscharEx Phase 2 Adaptive Design Study","therapeuticArea":"Podiatry","highestDevelopmentStatus":"Phase II","country":"ISRAEL","productType":"Large molecule","productStatus":"New Molecular Entity","date":"June 2021","url1":"","url2":"","graph1":"Large molecule","graph2":"Phase II"},{"orgOrder":0,"company":"Cynata Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Ethics Approval for Cynata\u2019s Clinical Trial in Diabetic Foot Ulcers","therapeuticArea":"Podiatry","highestDevelopmentStatus":"Preclinical","country":"AUSTRALIA","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"June 2021","url1":"","url2":"","graph1":"Cell and Gene therapy","graph2":"Preclinical"},{"orgOrder":0,"company":"MediWound","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"MediWound Announces Positive Outcome of Interim Assessment for its EscharEx U.S. Phase 2 Adaptive Design Study","therapeuticArea":"Podiatry","highestDevelopmentStatus":"Phase II","country":"ISRAEL","productType":"Large molecule","productStatus":"New Molecular Entity","date":"July 2021","url1":"","url2":"","graph1":"Large molecule","graph2":"Phase II"},{"orgOrder":0,"company":"MediWound","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"MediWound Completes Enrollment of its EscharEx U.S. Phase 2 Adaptive Design Study","therapeuticArea":"Podiatry","highestDevelopmentStatus":"Phase II","country":"ISRAEL","productType":"Large molecule","productStatus":"New Molecular Entity","date":"December 2021","url1":"","url2":"","graph1":"Large molecule","graph2":"Phase II"},{"orgOrder":0,"company":"Aurealis Therapeutics","sponsor":"Xbiome","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Aurealis Therapeutics and Xbiome Enter into a License and Collaboration Agreement for Aurealis Four-in-One Diabetic Foot Ulcer and Inflammatory Disease Cell and Gene Therapy AUP-16 in Greater China","therapeuticArea":"Podiatry","highestDevelopmentStatus":"Phase I\/ Phase II","country":"SWITZERLAND","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"January 2022","url1":"","url2":"","graph1":"Cell and Gene therapy","graph2":"Phase I\/ Phase II"},{"orgOrder":0,"company":"Lakewood-Amedex","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Lakewood-Amedex Enrolls First Patient in Phase 2 Clinical Trial for Patients with Chronic Diabetic Foot Ulcers (cDFU)","therapeuticArea":"Podiatry","highestDevelopmentStatus":"Phase II","country":"U.S.A","productType":"Small molecule","productStatus":"New Molecular Entity","date":"April 2022","url1":"","url2":"","graph1":"Small molecule","graph2":"Phase II"},{"orgOrder":0,"company":"MediWound","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"MediWound Announces Positive Results from its U.S. Phase 2 Pharmacology Study of EscharEx for Debridement of Lower Leg Ulcers","therapeuticArea":"Podiatry","highestDevelopmentStatus":"Phase II","country":"ISRAEL","productType":"Large molecule","productStatus":"New Molecular Entity","date":"July 2022","url1":"","url2":"","graph1":"Large molecule","graph2":"Phase II"},{"orgOrder":0,"company":"Promore Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Promore Pharma Granted EU Patent Regarding Treatment of Chronic Wounds","therapeuticArea":"Podiatry","highestDevelopmentStatus":"Phase II","country":"SWEDEN","productType":"Peptide","productStatus":"New Molecular Entity","date":"August 2022","url1":"","url2":"","graph1":"Peptide","graph2":"Phase II"},{"orgOrder":0,"company":"MiMedx","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"MIMEDX EPIFIX\u00ae Receives Reimbursement Approval in Japan","therapeuticArea":"Podiatry","highestDevelopmentStatus":"Approved","country":"U.S.A","productType":"Cell and Gene therapy","productStatus":"Approved","date":"September 2022","url1":"","url2":"","graph1":"Cell and Gene therapy","graph2":"Approved"},{"orgOrder":0,"company":"CellResearch Corporation","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Cell Research Corporation (CRC) Announces Positive Results of Phase I Study for CorLiCyte\u00ae","therapeuticArea":"Podiatry","highestDevelopmentStatus":"Phase I","country":"SINGAPORE","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"September 2022","url1":"","url2":"","graph1":"Cell and Gene therapy","graph2":"Phase I"},{"orgOrder":0,"company":"MiMedx","sponsor":"Gunze Medical Limited","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"MIMEDX Announces Commercial Launch of EPIFIX\u00c2\u00ae in Japan with Exclusive Distribution Agreement with Gunze Medical Limited","therapeuticArea":"Podiatry","highestDevelopmentStatus":"Approved","country":"U.S.A","productType":"Cell and Gene therapy","productStatus":"Approved","date":"January 2023","url1":"","url2":"","graph1":"Cell and Gene therapy","graph2":"Approved"}]
Find Clinical Drug Development Pipelines & Deals | PipelineProspector
EPIFIX (human amnion membrane allograft) is a PURION® processed placental tissue allograft that supports the healing cascade by providing a semi-permeable, protective barrier over wounds.
CorLiCyte® is a live mesenchymal stem cell therapy derived from human umbilical cord lining stem cells, with a proprietary optimised expression of cytokines, growth and cellular factors for the treatment of a number of serious health conditions.
Lead Product(s):
Human Umbilical Cord Derived Mesenchymal Stem Cells
EPIFIX (Human Amnion-chorion Membrane Allograft) is a PURION® processed placental tissue allograft that supports the healing cascade by providing a protective barrier over wounds.
The most important finding from that clinical trial was that ropocamptide (LL-37) shows a significant effect in the patient subgroup with large wounds (≥10 cm2).
EscharEx (proteolytic enzymes enriched bromelain) is a bioactive therapy for debridement of chronic and other hard-to-heal wounds in advanced stages of clinical development, is easy-to-use concentrate of proteolytic enzymes enriched in bromelain for topical daily applications.
Lead Product(s):
Bromelain Enriched Proteolytic Enzyme
Bisphosphocins are novel small protonated nucleotide derivative molecules that exert their antibacterial activity by depolarization and rupture of the bacterial cell membranes, causing rapid bacterial cell death.
Under the terms of the license and collaboration agreement, Xbiome acquires exclusive development and commercial rights for all human use to Aurealis clinical stage DFU drug candidate AUP-16 in Mainland China, Hong Kong, Macao, and Taiwan.
U.S. phase 2 trial of EscharEx (Proteolytic enzymes enriched in bromelain) as a non-surgical rapid and effective debridement agent with the potential to improve on the current standard of care for chronic wound management.
Lead Product(s):
Proteolytic Enzymes Enriched In Bromelain
The study is expected to enroll 120 patients at approximately 20 clinical sites, primarily in U.S. Study participants are randomized to either EscharEx, placebo control or non-surgical soc of either enzymatic or autolytic debridement, at ratio of 3:3:2, with 3 month follow-up.
Lead Product(s):
Proteolytic Enzymes Enriched in Bromelain
This will be the first clinical trial to utilise CYP-006TK, a polymer-coated silicon dressing (seeded with Cymerus MSCs) that Cynata has licensed from TekCyte Pty Ltd (TekCyte).
Market Place
Company
Upload your Marketing & Sales content on your company Virtual Booth, click HERE
